C1orf106 is a colitis risk gene that regulates stability of epithelial adherens junctions
- PMID: 29420262
- PMCID: PMC6008784
- DOI: 10.1126/science.aan0814
C1orf106 is a colitis risk gene that regulates stability of epithelial adherens junctions
Abstract
Polymorphisms in C1orf106 are associated with increased risk of inflammatory bowel disease (IBD). However, the function of C1orf106 and the consequences of disease-associated polymorphisms are unknown. Here we demonstrate that C1orf106 regulates adherens junction stability by regulating the degradation of cytohesin-1, a guanine nucleotide exchange factor that controls activation of ARF6. By limiting cytohesin-1-dependent ARF6 activation, C1orf106 stabilizes adherens junctions. Consistent with this model, C1orf106-/- mice exhibit defects in the intestinal epithelial cell barrier, a phenotype observed in IBD patients that confers increased susceptibility to intestinal pathogens. Furthermore, the IBD risk variant increases C1orf106 ubiquitination and turnover with consequent functional impairments. These findings delineate a mechanism by which a genetic polymorphism fine-tunes intestinal epithelial barrier integrity and elucidate a fundamental mechanism of cellular junctional control.
Copyright © 2018 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.
Conflict of interest statement
Comment in
-
IBD: Functional characterization of an IBD risk gene.Nat Rev Gastroenterol Hepatol. 2018 Apr;15(4):190-191. doi: 10.1038/nrgastro.2018.17. Epub 2018 Feb 21. Nat Rev Gastroenterol Hepatol. 2018. PMID: 29463905 No abstract available.
-
Intestinal barriers protect against disease.Science. 2018 Mar 9;359(6380):1097-1098. doi: 10.1126/science.aat0835. Science. 2018. PMID: 29590026 No abstract available.
Similar articles
-
Inflammatory Bowel Disease Susceptibility Gene C1ORF106 Regulates Intestinal Epithelial Permeability.Immunohorizons. 2018 May 30;2(5):164-171. doi: 10.4049/immunohorizons.1800027. Immunohorizons. 2018. PMID: 31022698
-
Neutrophil transmigration in inflammatory bowel disease is associated with differential expression of epithelial intercellular junction proteins.Am J Pathol. 2001 Dec;159(6):2001-9. doi: 10.1016/S0002-9440(10)63051-9. Am J Pathol. 2001. PMID: 11733350 Free PMC article.
-
The satiety factor apolipoprotein A-IV modulates intestinal epithelial permeability through its interaction with alpha-catenin: implications for inflammatory bowel diseases.Horm Metab Res. 2007 Aug;39(8):601-11. doi: 10.1055/s-2007-984466. Horm Metab Res. 2007. PMID: 17712726
-
Inflammatory bowel disease and the apical junctional complex.Ann N Y Acad Sci. 2006 Aug;1072:242-52. doi: 10.1196/annals.1326.017. Ann N Y Acad Sci. 2006. PMID: 17057204 Review.
-
Disruption of the epithelial barrier during intestinal inflammation: Quest for new molecules and mechanisms.Biochim Biophys Acta Mol Cell Res. 2017 Jul;1864(7):1183-1194. doi: 10.1016/j.bbamcr.2017.03.007. Epub 2017 Mar 18. Biochim Biophys Acta Mol Cell Res. 2017. PMID: 28322932 Free PMC article. Review.
Cited by
-
C1orf106 (INAVA) Is a SMAD3-Dependent TGF-β Target Gene That Promotes Clonogenicity and Correlates with Poor Prognosis in Breast Cancer.Cells. 2024 Sep 12;13(18):1530. doi: 10.3390/cells13181530. Cells. 2024. PMID: 39329715 Free PMC article.
-
Challenges in IBD Research 2024: Preclinical Human IBD Mechanisms.Inflamm Bowel Dis. 2024 May 23;30(Supplement_2):S5-S18. doi: 10.1093/ibd/izae081. Inflamm Bowel Dis. 2024. PMID: 38778627 Free PMC article. Review.
-
Genetic mapping across autoimmune diseases reveals shared associations and mechanisms.Nat Genet. 2024 May;56(5):838-845. doi: 10.1038/s41588-024-01732-8. Epub 2024 May 13. Nat Genet. 2024. PMID: 38741015
-
Sirt2 inhibition improves gut epithelial barrier integrity and protects mice from colitis.Proc Natl Acad Sci U S A. 2024 Apr 30;121(18):e2319833121. doi: 10.1073/pnas.2319833121. Epub 2024 Apr 22. Proc Natl Acad Sci U S A. 2024. PMID: 38648480 Free PMC article.
-
Btbd8 deficiency reduces susceptibility to colitis by enhancing intestinal barrier function and suppressing inflammation.Front Immunol. 2024 Mar 15;15:1382661. doi: 10.3389/fimmu.2024.1382661. eCollection 2024. Front Immunol. 2024. PMID: 38558797 Free PMC article.
References
-
- Mankertz J, Schulzke JD. Altered permeability in inflammatory bowel disease: Pathophysiology and clinical implications. Curr Opin Gastroenterol. 2007;23:379–383. - PubMed
-
- Hollander D, Vadheim CM, Brettholz E, Petersen GM, Delahunty T, Rotter JI. Increased intestinal permeability in patients with Crohn’s disease and their relatives. A possible etiologic factor. Ann Intern Med. 1986;105:883–885. - PubMed
-
- Anderson CA, Boucher G, Lees CW, Franke A, D’Amato M, Taylor KD, Lee JC, Goyette P, Imielinski M, Latiano A, Lagacé C, Scott R, Amininejad L, Bumpstead S, Baidoo L, Baldassano RN, Barclay M, Bayless TM, Brand S, Büning C, Colombel JF, Denson LA, De Vos M, Dubinsky M, Edwards C, Ellinghaus D, Fehrmann RSN, Floyd JAB, Florin T, Franchimont D, Franke L, Georges M, Glas J, Glazer NL, Guthery SL, Haritunians T, Hayward NK, Hugot JP, Jobin G, Laukens D, Lawrance I, Lémann M, Levine A, Libioulle C, Louis E, McGovern DP, Milla M, Montgomery GW, Morley KI, Mowat C, Ng A, Newman W, Ophoff RA, Papi L, Palmieri O, Peyrin-Biroulet L, Panés J, Phillips A, Prescott NJ, Proctor DD, Roberts R, Russell R, Rutgeerts P, Sanderson J, Sans M, Schumm P, Seibold F, Sharma Y, Simms LA, Seielstad M, Steinhart AH, Targan SR, van den Berg LH, Vatn M, Verspaget H, Walters T, Wijmenga C, Wilson DC, Westra HJ, Xavier RJ, Zhao ZZ, Ponsioen CY, Andersen V, Torkvist L, Gazouli M, Anagnou NP, Karlsen TH, Kupcinskas L, Sventoraityte J, Mansfield JC, Kugathasan S, Silverberg MS, Halfvarson J, Rotter JI, Mathew CG, Griffiths AM, Gearry R, Ahmad T, Brant SR, Chamaillard M, Satsangi J, Cho JH, Schreiber S, Daly MJ, Barrett JC, Parkes M, Annese V, Hakonarson H, Radford-Smith G, Duerr RH, Vermeire S, Weersma RK, Rioux JD. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet. 2011;43:246–252. - PMC - PubMed
-
- Rivas MA, Beaudoin M, Gardet A, Stevens C, Sharma Y, Zhang CK, Boucher G, Ripke S, Ellinghaus D, Burtt N, Fennell T, Kirby A, Latiano A, Goyette P, Green T, Halfvarson J, Haritunians T, Korn JM, Kuruvilla F, Lagacé C, Neale B, Lo KS, Schumm P, Törkvist L, Dubinsky MC, Brant SR, Silverberg MS, Duerr RH, Altshuler D, Gabriel S, Lettre G, Franke A, D’Amato M, McGovern DPB, Cho JH, Rioux JD, Xavier RJ, MJ DalyNational Institute of Diabetes and Digestive Kidney Diseases Inflammatory Bowel Disease Genetics Consortium (NIDDK IBDGC)United Kingdom, Inflammatory Bowel Disease Genetics ConsortiumInternational Inflammatory Bowel Disease Genetics Consortium. Deep resequencing of GWAS loci identifies independent rare variants associated with inflammatory bowel disease. Nat Genet. 2011;43:1066–1073. - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
